JPMorgan downgraded Sarepta (SRPT) to Neutral from Overweight with a price target of $16, down from $20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target lowered to $25 from $50 at BMO Capital
- Sarepta price target lowered to $11 from $18 at Piper Sandler
- Sarepta Stock (SRPT) Could Crash to $0, Warns Wainwright Analyst
- Sarepta Therapeutics’ Shipment Pause of Elevidys: Strategic Move Amidst Regulatory Concerns
- Sarepta downgraded to Equal Weight from Overweight at Barclays